{"filing":{"accession_number":"0001193125-26-236933","cik":"0001847903","ticker":"CNTA","company_name":"Centessa Pharmaceuticals plc","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"d156443d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1847903/000119312526236933/d156443d8k.htm"},"events":[{"id":10568,"run_id":9270,"accession_number":"0001193125-26-236933","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"The filing discloses the expiration of the Hart-Scott-Rodino Act waiting period for Eli Lilly's acquisition of Centessa Pharmaceuticals plc, a material milestone in the transaction announced on March 31, 2026. The disclosure explicitly states this satisfies \"one of the conditions to the closing of the Acquisition\" and references the Transaction Agreement, Scheme of Arrangement, and pending shareholder approval and High Court sanction—all hallmarks of a material M\u0026A transaction that would significantly affect the registrant's future.","company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","filing_date":"2026-05-22","form":"8-K","submitted_at":null,"items":[{"id":6909,"accession_number":"0001193125-26-236933","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses the expiration of the Hart-Scott-Rodino Act waiting period for Eli Lilly's acquisition of Centessa Pharmaceuticals plc, a material milestone in the transaction announced on March 31, 2026. The disclosure explicitly states this satisfies \"one of the conditions to the closing of the Acquisition\" and references the Transaction Agreement, Scheme of Arrangement, and pending shareholder approval and High Court sanction—all hallmarks of a material M\u0026A transaction that would significantly affect the registrant's future.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:28:29.022541+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6909,"accession_number":"0001193125-26-236933","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses the expiration of the Hart-Scott-Rodino Act waiting period for Eli Lilly's acquisition of Centessa Pharmaceuticals plc, a material milestone in the transaction announced on March 31, 2026. The disclosure explicitly states this satisfies \"one of the conditions to the closing of the Acquisition\" and references the Transaction Agreement, Scheme of Arrangement, and pending shareholder approval and High Court sanction—all hallmarks of a material M\u0026A transaction that would significantly affect the registrant's future.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:28:29.022541+00:00","company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","filing_date":"2026-05-22"}]}